Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities
Net loss	$ (2,779)	$ (2,127)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of patent portfolio	681	1,062
Change in fair value of warrant liabilities	1,326	(1,031)
Stock-based compensation	11	299
Depreciation expenses	2	1
Realized loss on marketable securities	129	57
Unrealized gain on marketable securities	(137)	(29)
Changes in assets and liabilities:
Prepaid expenses and other assets	40	231
Accounts payable and accrued expenses	(20)	(124)
Accrued salaries and benefits	(364)	(571)
Deferred revenue	(618)	4,126
Accrued lease liabilities	(87)	(90)
Net cash (used in) provided by operating activities	(1,816)	1,804
Cash flows from investing activities
Purchase of marketable securities	(6,510)	(10,193)
Purchase of property and equipment		(3)
Sale of marketable securities	9,624	7,886
Investment in Hoth Therapeutics, Inc.	(675)
Net cash provided by (used in) investing activities	2,439	(2,310)
Cash flows from financing activities
Cash paid for cancellation of common stock		(4)
Proceeds from exercise of warrants		760
Repurchase of restricted stock units to pay for employee withholding taxes	(24)
Net cash (used in) provided byfinancing activities	(24)	756
Net increase in cash and cash equivalents	599	250
Cash and cash equivalents, beginning of period	134	142
Cash and cash equivalents, end of period	733	392
Cash paid for interest and taxes	114
Non-cash investing and financing activities
Extinguishment of Series H Convertible Preferred Stock in connection with license agreement		31,480
Recognition of deferred revenue in connection with license agreement		$ 414